Physicians' Academy for Cardiovascular Education

Discontinuation of the MILANO-PILOT trial, in which a cholesterol efflux promoter was being evaluated

News - Nov. 9, 2016

The Medicines Company discontinues the development of MDCO-216, a cholesterol efflux promoter. MDCO-216 is a complex of dimeric recombinant apolipoprotein A-1 Milano and a phospholipid (POPC), and mimics pre-beta HDL. MDCO-216 thereby induces cholesterol efflux, which should have resulted in plaque reduction and improved cardiovascular outcomes. However, according to the press release “the recently completed MILANO-PILOT trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development.”
 
The MILANO-PILOT study was a proof-of-concept, double-blind, placebo-controlled, randomized study in which the impact on cholesterol efflux by MDCO-216 was measured in 120 ACS patients, using intravascular ultrasound (IVUS). Although the efficacy results were disappointing, the drug showed an excellent safety profile of weekly 20 mg/kg MDCO-216 infusions over a 5-week period.
 
The efficacy results from the MILANO-PILOT trial in combination with the evolving treatment landscape for atherosclerotic cardiovascular disease, including the emergence of highly-positive data from the company’s PCSK9 synthesis inhibitor (ORION-1 trial), drove the company’s decision for discontinuation of MDCO-216. Results from the MILANO-PILOT trial will be presented in the Late-Breaking Clinical Trial Session at American Heart Association (AHA) Scientific Sessions this year in New Orleans. 
 

Source

Press release The Medicines Company, November 7, 2016

 

Share this page with your colleagues and friends: